Cellebrite DI Ltd.

03/18/2026 | Press release | Distributed by Public on 03/18/2026 05:16

Initial Statement of Beneficial Ownership (Form 3)

FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
CLAMMER ADAM
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
Cellebrite DI Ltd. [CLBT]
(Last) (First) (Middle)
FOUR EMBARCADERO CENTER, SUITE 2100
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) __X__ Other (specify below)
Chair of the Board
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)
SAN FRANCISCO, CA 94111
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Ordinary Shares 71,396(1) D
Ordinary Shares 13,861,007(2) I By TWC Tech Holdings II, LLC(3)(4)
Ordinary Shares 375,000 I By Long Term Trust(4)
Ordinary Shares 375,000 I By Joint Revocable Trust(4)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
CLAMMER ADAM
FOUR EMBARCADERO CENTER
SUITE 2100
SAN FRANCISCO, CA 94111
X Chair of the Board

Signatures

/s/ Sara Bockey, Attorney-in-Fact 03/18/2026
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Includes 10,601 time-based restricted stock units ("RSUs") granted under the Cellebrite DI Ltd. (the "Issuer") 2021 Share Incentive Plan which vest on September 17, 2026.
(2) Includes 1,500,000 ordinary shares of the Issuer subject to transfer restrictions pending the satisfaction of certain performance-based vesting conditions.
(3) As one of the managing members of the ultimate controlling entity of TWC Tech Holdings II, LLC, Mr. Clammer may be deemed to have shared beneficial ownership of the securities held directly by TWC Tech Holdings II, LLC.
(4) Mr. Clammer disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, Mr. Clammer states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Remarks:
Exhibit List: Exhibit 24 - Power of Attorney.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Cellebrite DI Ltd. published this content on March 18, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 18, 2026 at 11:16 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]